Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Skin Irritation Potential of MOB015B
NCT06369675Phase 1Completed
- Sponsor
- Moberg Pharma AB
- Start
- Oct 2017
- Primary completion
- Nov 2017
- Modality
- Transdermal Patches, Orthosteric Ligands, Hydrogel Systems
- Countries
- 1
01
Overview
Phase 1, randomised, single-blind trial of Terclara in onychomycosis, sponsored by Moberg Pharma AB. Primary endpoints: Skin Irritation Potential at 22 days and Safety Assessment at 22 days. Started Oct 2017; status: completed.
02
Drugs
Terclara
03
Conditions
onychomycosis
Beyond the preview
Go deeper on NCT06369675.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06369675.